Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569770 | PMC |
| http://dx.doi.org/10.1007/s40257-022-00705-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors.
Eur J Cancer
January 2025
Department of Dermatology, CHU Bordeaux, Bordeaux F-33000, France; Bordeaux Institute of Oncology, INSERM U1312, Team Translational Research on Oncodermatology and Orphean Skin Diseases, Univ. Bordeaux, Bordeaux F-33000, France. Electronic address:
Introduction: Immune checkpoint inhibitors (ICI) have become the first-line therapy in patients with advanced cutaneous squamous cell carcinoma (cSCC). Antibiotics (ATB) have been reported to reduce ICI response in cancers, but this has not been evaluated in cSCC.
Aim: To evaluate ATB exposure at the onset of ICI in cSCC patients and to analyze its impact on outcome.
Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review.
Arch Dermatol Res
January 2025
Department of Dermatology, College of Medicine, The Ohio State University Wexner Medical Center, 540 Officenter Place, Columbus, OH, 43230, USA.
The use of immunotherapy is an emerging treatment option for advanced malignancies. Cutaneous adverse events following cancer immunotherapy are well-documented in the literature. The rarer cutaneous adverse effects are less characterized, including eruptive keratoacanthomas (KA).
View Article and Find Full Text PDFAdvances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.
View Article and Find Full Text PDFReal-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée).
Oncologist
October 2024
Dermatology Department, University Hospital of Nice, Nice, France.
Background: Currently, treatment options for patients with advanced melanoma who experience failed immunotherapy or targeted therapy are lacking. Recent studies suggest the antitumor activity of combined pembrolizumab and lenvatinib in patients with advanced melanoma progressing on immunotherapy. Herein, we report the clinical outcomes of combined lenvatinib and a programmed cell death protein-1 inhibitor (PD-1) in this population.
View Article and Find Full Text PDFRadiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network.
J Eur Acad Dermatol Venereol
June 2024
Dermatology Department, CH Pau, Pau, France.
Background: Cutaneous adnexal carcinomas are a heterogeneous group of rare neoplasms. Surgical excision is the first-line treatment in localized stage. The use and effectiveness of radiotherapy have not been thoroughly evaluated in these neoplasms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!